Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ: MDWD )

17.83 -0.06 (-0.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients... 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Participate in Two Upcoming Investor Conferences
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
From MediWound Ltd.
Via GlobeNewswire
Recap: MediWound Q3 Earnings
Via Benzinga
Earnings Outlook For MediWound
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for MediWound: Here's What You Need To Know
Via Benzinga
Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development
Biopharmaceutical company MediWound Ltd (NASDAQ: MDWD) reported that the U.S. 
Via Benzinga
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement 
From MediWound Ltd.
Via GlobeNewswire
What 4 Analyst Ratings Have To Say About MediWound
Via Benzinga
Earnings Outlook For MediWound
Via Benzinga
Earnings Scheduled For November 21, 2023
Companies Reporting Before The Bell • Golden Ocean Group (NASDAQ:GOGL) is likely to report quarterly earnings at $0.11 per share on revenue of $149.42 million. 
Via Benzinga
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Third Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
The label expansion will solidify NexoBrid’s position in the EU as a safe and effective non-surgical treatment for burn patients of all ages 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
NexoBrid complements PMI’s portfolio, allowing it to provide a comprehensive solution for burn patients 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
MediWound to join forces with 3M Health Care, world’s largest wound care company in pivotal study for patients with venous leg ulcers 
From MediWound Ltd.
Via GlobeNewswire
MediWound Deploys NexoBrid® for Emergency Supply
From MediWound Ltd.
Via GlobeNewswire
Q4 Stock Predictions: 3 Micro-Cap Stocks Ready to Skyrocket Into 2024
These Q4 micro-cap stocks are the ones to buy in on for long-term growth and returns to any investor's portfolio. 
Via InvestorPlace
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns 
From MediWound Ltd.
Via GlobeNewswire
MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress
From MediWound Ltd.
Via GlobeNewswire
MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference
From MediWound Ltd.
Via GlobeNewswire
MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Second Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Commercial Launch of NexoBrid® in Japan
Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement 
From MediWound Ltd.
Via GlobeNewswire
3 Micro-Cap Stocks to Buy for Multibagger Returns
These are the micro-cap stocks to buy and they represent companies with decent fundamentals and visibility for robust growth. 
Via InvestorPlace
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
From MediWound Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.